505(b)(2) Strategy Development
We design strategic development pathways that leverage existing clinical, scientific, and regulatory data to streamline development and accelerate approval timelines. Our approach helps reduce development costs while strengthening regulatory outcomes.
We support sponsors in identifying efficient development strategies and aligning scientific, clinical, and regulatory planning to enable faster, more confident market readiness.
Utilizing existing clinical and regulatory data to design faster, more efficient development pathways.
Value-Added Product Positioning
Developing differentiated product concepts and strategic 505(b)(2) positioning to maximize development and commercial potential.
Literature-Based Evidence Strategy
Leveraging published scientific and clinical evidence to strengthen the regulatory package and reduce development burden.
Gap Analysis & Clinical Bridging Strategy
Assessing reference products and defining clinical bridging approaches to address development gaps efficiently.
Regulatory Agency Engagement
Preparing strategic plans for FDA interactions and regulatory communications to support efficient approvals.
Technical & Safety Gap Assessment
Evaluating technical, safety, and efficacy gaps against the Reference Listed Drug (RLD) to guide development priorities.
IP Landscape & Patent Strategy Alignment
Assessing freedom-to-operate, patent strategy alignment, and IP-regulatory integration to support informed development decisions.
Targeted Development Roadmap
Designing streamlined development plans to optimize timelines, costs, and regulatory milestones.
Clinical Differentiation Strategy
Defining clinical positioning strategies that enhance product differentiation and strengthen market opportunity